Illumina, Inc. is a genomics company that develops DNA sequencing and array-based life sciences technologies. Its business segments include next-generation sequencing (NGS) platforms, microarrays, library preparation kits, and data analysis software. Key products include the NovaSeq X, MiSeq i100 Series, and the Illumina BioInsight Platform. The company also offers NGS-based proteomics services and spatial technology solutions such as Illumina StrataMap Spatial. Illumina serves customers in disease research, drug discovery, clinical diagnostics, and personalized health, with applications in oncology, genetic and infectious diseases, and reproductive health. The company was founded in 1998 and operates globally, providing tools for researchers, clinicians, and laboratories to analyze genomic data.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Medical Devices Homepage illumina.com
Sector Healthcare IR page investor.illumina.com
Tags
next-generation sequencing, genomics, microarrays, library preparation, bioinformatics, proteomics, spatial biology, clinical diagnostics, drug discovery, precision medicine, NovaSeq X, MiSeq i100 Series, Illumina BioInsight Platform, Illumina StrataMap Spatial, Illumina Protein Prep, SOMAmer, NGS Workflow Finder, Sequencing Method Explorer
Press page —

Metrics

Valuation  
Market cap $ 32.867B
Market cap (USD) $ 32.867B
P/E 37.41
PEG —
P/BV 10.45
P/S 7.24
P/OCF 26.72
P/FCF 31.09
Dividend yield —
Turnover / mcap —
Returns  
ROE 33.4%
ROI 18.0%
ROIC 13.4%
Profit margin 19.6%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 73.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 30
Quality score 16.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 4.343B 4.372B 4.504B 4.584B 4.526B 3.239B 3.543B 3.333B 2.752B 2.398B 2.22B 1.861B 1.421B 1.149B 1.056B 902.741M 666.324M 573.225M 366.799M 184.586M 73.501M 50.583M 28.035M 10.04M — —
Net profit 850M -1.223B -1.161B -4.404B 762M 656M 1.002B 826M 726M 462.649M 461.559M 353.351M 125.308M 151.254M 86.628M 124.891M 72.281M 50.477M -278.359M 39.968M -20.874M -6.225M -27.063M -40.331M -24.823M —
Free cash flow 931M 709M 283M 106M 337M 891M 842M 846M 565M 427.347M 516.749M 395.275M 307.206M 223.092M 280.34M 222.755M 119.518M 28.189M 31.951M 23.886M -20.403M -22.929M -20.288M -52.423M -25.897M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 131.16 133.63 139.24 202.2 380.44 370 331.74 299.93 218.49 128.04 191.95 184.58 110.59 55.6 30.48 63.37 30.67 26.05 59.79 38.59 15.13 — — — — —
Price performance 12m -0.02 -0.04 -0.31 -0.47 0.03 0.12 0.11 0.37 0.71 -0.33 0.04 0.67 0.99 0.82 -0.52 1.07 0.18 -0.56 0.55 1.55 — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 381M 411M 514M 573M 487M 648M 671M 734M 735M 854M
↳ YoY growth -1.1% +7.8% +25.1% +11.5% -15.0% +33.1% +3.5% +9.4% +0.1% +16.2%
↳ 5y CAGR +17.0% +13.8% +16.6% +14.6% +4.8% +11.2% +10.3% +7.4% +5.1% +11.9%
Borrowings, current (USD) 1.25M 10M 1.11B 0.00 511M 0.00 — — — —
Borrowings, non-current (USD) 1.05B 1.18B 890M 1.14B 673M — — — — —
Lease liabilities (USD) — — 722M 740M 722M 845M 820M 773M 633M 564M
Cash and deposits (USD) 735M 1.23B 1.14B 2.04B 1.81B 1.23B 2.01B 1.05B 1.13B 1.42B
Intangible assets (USD) 243M 175M 185M 145M 142M 3.25B 3.29B 2.99B 295M 210M
Right-of-use assets (USD) — — 579M 555M 532M 672M 653M 544M 419M 370M
Net debt (borrowings + leases - cash) (USD) 315M -33M 853M -161M 96M -387M — — — —
Cash flow detail
Operating cash flow (USD) 687M 875M 1.14B 1.05B 1.08B 545M 392M 478M 837M 1.08B
Purchases of property, plant and equipment (USD) -260M -310M -296M -209M -189M -208M -286M -195M -128M -148M
Purchases of intangible assets (USD) -11.5M -2M — — 0.00 0.00 -180M -1M — —
Change in receivables (cash effect) (USD) 3.24M -26M -105M -58M 89M -164M -12M -40M -25M -108M
Change in inventories (cash effect) (USD) -29.7M -33M -53M 25M -12M -58M -135M -20M 19M -17M
Change in payables (cash effect) (USD) -1.97M 10M 45M -35M 40M 60M -38M -44M -4M 2M
Share buybacks (cash effect) (USD) -249M -251M -201M -324M -736M 0.00 0.00 0.00 -116M -742M
Interest paid (cash effect) (USD) — — — — — -9M -17M -73M -83M -95M
Income taxes paid (cash effect) (USD) -59.7M -149M -99M -164M -119M -233M -122M -65M -105M -73M
Share-based compensation (USD) 129M 164M 193M 194M 194M 754M 366M 380M 370M 275M
Operating cash flow before change in receivables (USD) 684M 901M 1.25B 1.11B 991M 709M 404M 518M 862M 1.19B
Free cash flow (OCF - PPE - intangibles) (USD) 416M 563M 846M 842M 891M 337M -74M 282M 709M 931M
Income detail
Research and development expense (USD) 504M 546M 623M 647M 682M 1.19B 1.32B 1.35B 1.17B 967M
↳ 5y CAGR +20.7% +18.8% +17.6% +10.8% +11.2% +18.6% +19.3% +16.8% +12.6% +7.2%
Total comprehensive income (USD) 427M 678M 782M 996M 653M 777M -4.42B -1.17B -1.2B 818M
Comprehensive income to owners (USD) 462M 726M 826M 1.01B 653M 777M -4.42B -1.17B -1.2B 818M
Reported Feb 14, 2017 Feb 13, 2018 Apr 26, 2019 Feb 11, 2020 Feb 17, 2023 Feb 16, 2024 Feb 16, 2024 Feb 12, 2026 Feb 12, 2025 Feb 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

View all Investor Information Bull 0 Bear 0 Not a release

Skip to content

Illumina is dedicated to improving human health by unlocking the power of the genome. Our portfolio of DNA sequencing, array-based technology, and multiomics solutions fuels advancements across life sciences, clinical medicine, and therapeutic discovery.

News Releases

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

November 2, 2026

Read More

Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026

October 29, 2026

Read More

Illumina To Webcast Upcoming Investor Conference

October 27, 2026

Read More

Events

Upcoming Events

Jefferies Global Healthcare Conference in London

November 17, 2026 | 10:30 AM GMT

Upcoming Events

UBS Global Healthcare Conference

November 10, 2026 | 7:15 AM PST

Past Events

Q3 2026 Illumina, Inc. Earnings Conference Call

October 29, 2026 | 1:30 PM PDT

Past Events

Q2 2026 Illumina, Inc. Earnings Conference Call

July 30, 2026 | 1:30 PM PDT

Past Events

Q1 2026 Illumina, Inc. Earnings Conference Call

April 30, 2026 | 1:30 PM PDT

Recent Reports

Q2 2026 Quarterly Report

Q1 2026 Quarterly Report

2026 Proxy Statement

2025 10-K

Q3 2025 Quarterly Report

Q2 2025 Quarterly Report

Q1 2025 Quarterly Report

Q3 2026 Results

Search Investors

Illumina Logo

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, or your device, and is mostly used to make the site work as you expect. The information does not usually identify you directly, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. Blocking some types of cookies may impact your experience of the site and the services we are able to offer. Cookie Policy

I agree, turn on my tailored experience

Manage Consent Preferences

Essential

Always Active

Necessary for the website to function. These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in, or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Functional

Functional

Enhances functionality and customization. These cookies enable the website to provide enhanced functionality and customization. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Social Media and Advertising

Social Media and Advertising

Builds a profile of interests for tailored ads from third parties and enables you to share content with friends and networks. These cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your browser across other sites and building up a profile of your interests. This may impact the content and messages you see on other websites you visit. If you do not allow these cookies you may not be able to use or see these sharing tools.

Website Performance

Website Performance

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. If you do not allow these cookies we will not know when you have visited our site and will not be able to monitor its performance.

Tailored Content

Tailored Content

Displays discounts, promotions, custom pricing, and content based on specific interests. These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookie List

Clear

checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Powered by Onetrust

San Diego, October 29, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) (“Illumina” or the “company”) today announced its financial results for the third quarter of fiscal year 2026.

Third quarter 2026 results

•Reported revenue was $1.13 billion for Q3 2026, up 4.2% from Q3 2025. Revenue excluding tariff refunds was $1.17 billion, up 4.7% after also excluding the impacts of currency, acquisitions, and the Greater China region (“ROW1 organic revenue growth”).

•GAAP operating margin was 27.0% and non‑GAAP operating margin, excluding tariff refunds, was 25.0%.

•GAAP diluted EPS was $1.43 and non‑GAAP diluted EPS, excluding tariff refunds, was $1.44.

“In the third quarter, healthy clinical demand and robust NovaSeq X placements drove results above our guidance. Based on continued momentum, we are raising our full year revenue and earnings guidance,” said Jacob Thaysen, Chief Executive Officer of Illumina. “As we continue to execute our strategy, our innovation is broadening the value of the Illumina ecosystem.

SAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2026 following the close of market on Thursday, October 29, 2026.

On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Conference Call Details

The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, October 29, 2026. Interested parties may access the live webcast via the Investor Info section of Illumina's website or directly through the following link – https://illumina-earnings-call-q3-2026.open-exchange.net. To ensure a timely connection, please join at least ten minutes before the scheduled start of the call.

A replay of the conference call will be posted on Illumina's website after the event and will be available for at least 30 days following.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube.

Investors: Conor McNamara +1.858.291.6421 [email protected]

Media: Christine Douglass [email protected]

Cision View original content:https://www.prnewswire.com/news-releases/illumina-to-announce-third-quarter-2026-financial-results-on-thursday-october-29-2026-302902965.html

SOURCE Illumina, Inc.

최근 기사

[What is epigenomics? A beginner’s guide to gene expression

What is epigenomics? A beginner’s guide to gene expression](https://www.illumina.com/content/illumina-marketing/spac/ko_KR/company/news-center/feature-articles/multiomics-explained-epigenomics.html) [Beyond the Human Genome Project: What’s next for genomics?

Beyond the Human Genome Project: What’s next for genomics?](https://www.illumina.com/content/illumina-marketing/spac/ko_KR/company/news-center/feature-articles/beyond-the-human-genome-project--what-s-next-for-genomics-.html) [“Changing the narrative”: What happens when Illumina adopts a school

“Changing the narrative”: What happens when Illumina adopts a school](https://www.illumina.com/content/illumina-marketing/spac/ko_KR/company/news-center/feature-articles/-changing-the-narrative---what-happens-when-illumina-adopts-a-sc.html)

Share

Share on Facebook Share on Twitter Share on Linkedin

×

Please select a location

This is the international website for Illumina. If you are looking for information specific to your region, please select your location and we will redirect you.

보다 관련성이 높은 콘텐츠를 확인하실 수 있습니다. 주요 관심 분야를 선택해 주세요:

×

암 연구

미생물학 연구

농업유전체학 연구

복합 질환 연구

임상 종양학 연구

생식 보건 연구

유전 및 희귀 질환 연구

선호 항목 삭제하기

보다 관련성이 높은 콘텐츠를 확인하실 수 있습니다. 주요 관심 분야를 선택해 주세요:

Illumina Logo

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, or your device, and is mostly used to make the site work as you expect. The information does not usually identify you directly, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. Blocking some types of cookies may impact your experience of the site and the services we are able to offer. Cookie Policy

I agree, turn on my tailored experience

Manage Consent Preferences

Essential

Always Active

Necessary for the website to function. These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in, or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Functional

Functional

Enhances functionality and customization. These cookies enable the website to provide enhanced functionality and customization. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Social Media and Advertising

Social Media and Advertising

Builds a profile of interests for tailored ads from third parties and enables you to share content with friends and networks. These cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your browser across other sites and building up a profile of your interests. This may impact the content and messages you see on other websites you visit. If you do not allow these cookies you may not be able to use or see these sharing tools.

Website Performance

Website Performance

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. If you do not allow these cookies we will not know when you have visited our site and will not be able to monitor its performance.

Tailored Content

Tailored Content

Displays discounts, promotions, custom pricing, and content based on specific interests. These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookie List

Clear

checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Powered by Onetrust

Feedback

Close

Prompts

Illumina, Inc. (ticker ILMN), listed in United States.

ETFs Holding Illumina, Inc.

ETF Weight in ETF Shares Market value As of
ARKG 4.67% 419,496 $ 84.994M Nov 18, 2026
FMTM 3.50% 43,050 $ 8.83M Jul 31, 2026
FMED 2.82% 6,800 $ 1.453M Aug 31, 2026
VNSE 2.80% 2,246 $ 394.914K Jun 30, 2026
SAMM 2.44% 4,215 $ 741.123K Jun 30, 2026
AMID 2.17% 12,430 $ 2.52M Nov 18, 2026
CVAR 1.86% 3,891 $ 798.044K Jul 31, 2026
BEEX 1.83% 17,252 $ 3.416M Nov 17, 2026
MTRA 1.79% 12,169 $ 2.496M Jul 31, 2026
QMOM 1.68% 31,612 $ 6.4M Nov 18, 2026
BAFE 1.52% 146,486 $ 25.757M Jun 30, 2026
BMED 1.38% 995 $ 197.01K Nov 16, 2026
BCSM 1.22% 2,293 $ 403.178K Jun 30, 2026
GPT 1.12% 1,510 $ 265.503K Jun 30, 2026
JTEK 1.10% 214,057 $ 43.37M Nov 17, 2026
ARKK 1.02% 639,067 $ 129.481M Nov 18, 2026
YOKE 0.95% 10,298 $ 2.09M Nov 18, 2026
FEMV 0.82% 246 $ 43.254K Jun 30, 2026
LSEQ 0.80% 680 $ 140.767K Nov 13, 2026
FMDE 0.78% 328,862 $ 57.824M Jun 30, 2026
HGRO 0.74% 4,557 $ 934.641K Jul 31, 2026
OASC 0.74% 3,248 $ 693.87K Aug 31, 2026
MMID 0.70% 1,191 $ 254.433K Aug 31, 2026
FTQI 0.68% 32,732 $ 6.481M Nov 16, 2026
FLCV 0.68% 4,426 $ 945.526K Aug 31, 2026
REMC 0.61% 117 $ 20.572K Jun 30, 2026
MKTN 0.60% 3,651 $ 641.955K Jun 30, 2026
ITAN 0.60% 3,641 $ 737.703K Nov 17, 2026
FLCC 0.55% 3,412 $ 728.906K Aug 31, 2026
LSGR 0.54% 25,818 $ 4.54M Jun 30, 2026
VFQY 0.50% 11,905 $ 2.543M Aug 31, 2026
SMIZ 0.47% 6,080 $ 1.299M Aug 31, 2026
BTAL short -0.44% -7,084 $ -1.246M Jun 30, 2026
CGMM 0.44% 79,990 $ 15.838M Nov 16, 2026
FELV 0.42% 76,459 $ 13.444M Jun 30, 2026
BAMV 0.38% 2,069 $ 442K Aug 31, 2026
AVMC 0.37% 10,352 $ 2.05M Nov 16, 2026
CLSE 0.37% 15,511 $ 3.314M Aug 31, 2026
PEPS 0.35% 573 $ 100.751K Jun 30, 2026
FELG 0.34% 109,070 $ 19.178M Jun 30, 2026
FELC 0.31% 138,968 $ 24.435M Jun 30, 2026
FHEQ 0.26% 11,829 $ 2.426M Jul 31, 2026
FYEE 0.25% 2,609 $ 535.106K Jul 31, 2026
SAGP 0.21% 920 $ 161.764K Jun 30, 2026
PHEQ 0.20% 1,614 $ 283.79K Jun 30, 2026
VFMF 0.20% 9,241 $ 1.974M Aug 31, 2026
LCTU 0.19% 10,779 $ 2.134M Nov 16, 2026
JGRO 0.19% 84,083 $ 17.036M Nov 17, 2026
IALT 0.18% 70,732 $ 14.005M Nov 16, 2026
FEAC 0.18% 261 $ 45.892K Jun 30, 2026
VFMO 0.16% 14,112 $ 3.015M Aug 31, 2026
FLSP 0.15% 7,968 $ 1.401M Jun 30, 2026
ORR short -0.12% -2,153 $ -440K Nov 18, 2026
IQSZ 0.11% 946 $ 194.025K Jul 31, 2026
AVUQ 0.11% 2,451 $ 485.298K Nov 16, 2026
LGDX 0.11% 748 $ 148.104K Nov 17, 2026
AAUS 0.08% 2,003 $ 410K Nov 18, 2026
MODL 0.08% 4,524 $ 795.455K Jun 30, 2026
XMAG 0.07% 734 $ 153.81K Nov 13, 2026
THRO 0.07% 36,752 $ 7.277M Nov 16, 2026
EBI 0.07% 2,121 $ 453.109K Aug 31, 2026
ACVF 0.06% 454 $ 93.115K Jul 31, 2026
AVLC 0.06% 4,854 $ 961.092K Nov 16, 2026
JEPI 0.06% 127,760 $ 25.885M Nov 17, 2026
FLCG 0.05% 1,521 $ 324.931K Aug 31, 2026
DFUS 0.05% 47,798 $ 10.016M Nov 12, 2026
DFSU 0.05% 5,211 $ 1.092M Nov 12, 2026
DFAU 0.04% 27,310 $ 5.723M Nov 12, 2026
AVUS 0.04% 29,798 $ 5.9M Nov 16, 2026
DYNF 0.04% 77,490 $ 15.343M Nov 16, 2026
JSTC 0.04% 548 $ 108.504K Nov 17, 2026
DFAC 0.04% 166,289 $ 34.846M Nov 12, 2026
TACU 0.04% 36 $ 7,128.00 Nov 17, 2026
NTSX 0.04% 2,809 $ 493.906K Jun 30, 2026
GDE 0.04% 809 $ 172.827K Aug 31, 2026
VOXP 0.03% 9 $ 1,845.90 Jul 31, 2026
NTSD 0.03% 62 $ 10.901K Jun 30, 2026
MSLC 0.03% 5,819 $ 1.243M Aug 31, 2026
AVSU 0.03% 725 $ 143.55K Nov 16, 2026
JUSA 0.03% 1,492 $ 302.294K Nov 17, 2026
DCOR 0.03% 54,351 $ 11.389M Nov 12, 2026
CSHP 0.02% 308 $ 60.984K Nov 16, 2026
VSLU 0.02% 573 $ 100.751K Jun 30, 2026
INRO 0.01% 203 $ 40.194K Nov 16, 2026
GSPY 0.01% 483 $ 95.634K Nov 17, 2026
NPFE 0.00% 41 $ 8,409.10 Jul 31, 2026
DXUV 0.00% 13 $ 2,724.15 Nov 12, 2026
IETC 0.00% 32 $ 6,336.00 Nov 16, 2026
CORO 0.00% 95 $ 18.858K Nov 16, 2026
GVLU 0.00% 16 $ 3,168.00 Nov 17, 2026